Puma Biotechnology, Inc. PBYI
Updated: 10 Aug 2026
No signal published yet
We already track Puma Biotechnology and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Puma Biotechnology, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Puma Biotechnology free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 6, 2026, Puma Biotechnology reported second-quarter 2026 total revenue of $56.5 million and net income of $8.2 million, returning to profitability. Driven by increased demand for NERLYNX, the company raised its full-year 2026 revenue and net income guidance. Additionally, Puma confirmed it is completely debt-free following the final principal payment on its loan obligations in May 2026.
What Firelda Watch includes for Puma Biotechnology, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Puma Biotechnology, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Puma Biotechnology free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more